Charles River is expanding its testing capabilities in Ballina as part of its partnership with Covid-19 vaccine manufacturer AstraZeneca.
Contract research organisation Charles River Laboratories is planning an €8m site expansion in Ballina to facilitate batch release testing for Covid-19 vaccines from AstraZeneca.
The expansion at the Mayo site will create an additional 1,500 sq m of lab space and 90 highly skilled jobs in the area over the next three years.
The company provides longstanding partners AstraZeneca with outsourced regulated safety and development support on a range of treatments and vaccines, including testing and facilitating the deployment of Vaxzevria for Covid-19 and Fluenz for seasonal infleunza.
The latest investment follows earlier expansions at the Ballina site and Charles River recently announced plans to establish a dedicated laboratory space to handle testing of SARS-CoV-2 and other similar pathogens that cause human disease.
“We are incredibly proud of the transformational changes we have implemented on site and the role that Charles River has played in supporting the safe and timely roll-out of AstraZeneca’s Covid-19 vaccine,” said Liam McHale, site director for Charles River Ballina.
“Throughout the pandemic, our site remained fully operational while keeping our employees safe and having a positive impact on human health. Our expanded facility will provide us with the increased capacity needed to continue the essential services we provide to our clients.”
Charles River acquired the Ballina facility, which focuses on biologics testing, in 2002. The company employs 230 people at its two facilities in Ireland, including the Mayo site and a site in Dublin, established in 2017, which serves as the EMEA and APAC headquarters for the company’s microbial solutions division.
IDA Ireland is supporting the expansion. Mary Buckley, executive director of the agency, said Charles River is an “employer of long standing” in Co Mayo.
“The enhancement of its product lines and the development of additional capability at the Ballina facility is most welcome,” she added. “Today’s announcement is strongly aligned to IDA Ireland’s regional pillar and its continued commitment to winning jobs and investment in regional locations.”
Dan Wygal, country president for AstraZeneca Ireland, added: “Our Covid-19 vaccine, Vaxzevria, undergoes extremely robust safety and quality testing prior to becoming available for patients. We are committed to bringing safe, effective vaccines to Ireland and other markets as quickly as possible, and Charles River will continue to be an important partner in this regard.”